EUVIMEDEUVIMED entdecken
Crossref

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data

Giacomo d'Andrea, Mauro Pettorruso, Giorgio Di Lorenzo, Taeho Greg Rhee, Stefania Chiappini, Rosalba Carullo, Stefano Barlati, Raffaella Zanardi, Gianluca Rosso, Marco Di Nicola, Ileana Andriola, Matteo Marcatili und 7 weitere

Journal of Affective Disorders · 2024-03 · 348 · 314-322

DOI: 10.1016/j.jad.2023.12.038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2024-03. Verfasst von Giacomo d'Andrea und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy. Hauptthemen laut MEDLINE: Ketamine, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: NIA NIH HHS, NIMH NIH HHS, NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Intravenous ketamine (KET-IV) and intranasal esketamine (ESK-NS) are effective in the acute treatment of Treatment-Resistant Depression (TRD). Studies comparing KET-IV and ESK-NS concerning their action, safety, and tolerability are currently lacking. MATERIALS AND METHODS: We combined patients' data from two unipolar TRD cohorts that received KET-IV (n = 171) at the Canadian Rapid Treatment Center of Excellence in Toronto, Canada, or ESK-NS (n = 140) at several TRD clinics in Italy. The Quick Inventory for Depression Symptomatology-Self-Report-16/QIDS-SR16 in the KET-IV group and Montgomery-Åsberg Depression Rating Scale/MADRS in the ESK-NS group measured depressive symptoms at baseline (T0) and after the acute treatment phase (T1) (i.e., four infusions of KET-IV and eight administrations of ESK-NS). As different scales were used, the primary outcome was to compare the improvement in depression severity in the two cohorts by measuring effect sizes, response and remission rates. Finally, we compare side effects and discontinuation rates. RESULTS: At T1, KET-IV and ESK-NS significantly reduced depressive symptoms (respectively: QIDS-SR16 mean reduction = 5.65, p < 0.001; MADRS mean reduction = 11.41, p = 0.025). KET-IV showed larger effect sizes compared to ESK-NS (1.666 vs. 1.244). KET-IV had higher response rates (36 % vs. 25 %; p = 0.042) but not superior remission rates (13 % vs. 12 %; p = 0.845) than ESK-NS at T1. Despite more reported side effects, KET-IV did not cause more discontinuations for adverse events (4.6 % vs. 2.12 %; p = 0.228) than ESK-NS. CONCLUSION: KET-IV showed a higher short-term antidepressant effect, whereas ESK-NS exhibited lower side effects. Both were generally well tolerated. Future head-to-head studies should consider the long-term efficacy of these treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineDepressive Disorder, Treatment-ResistantHumansCanadaAntidepressive AgentsDrug Therapy, CombinationDepressionTreatment Outcome

Stichwörter der Autor:innen

Comparative studyIntranasal esketamineIntravenous ketamineTRDTreatment-resistant depression

Substanzen

EsketamineKetamineAntidepressive Agents

Autor:innen und Institutionen

  • Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy.
  • Chair of Psychiatry, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy; IRCCS Fondazione Santa Lucia, Rome, Italy.
  • Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; VA New England Mental Illness, Research, Education and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, CT, USA; Department o…
  • Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, Brescia, Italy.
  • Mood Disorder Unit, Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Clinical Neurosciences, University Vita-Salute San Raffaele, Milan, Italy.
  • Department of Neurosciences Rita Levi Montalcini, University of Torino, Turin, Italy.

Förderung

  • NIA NIH HHS
  • NIMH NIH HHS
  • NIDA NIH HHS

Zitieren

APA

d'Andrea, G., Pettorruso, M., Di Lorenzo, G., Rhee, T. G., Chiappini, S., Carullo, R., Barlati, S., Zanardi, R., Rosso, G., Di Nicola, M., Andriola, I., Marcatili, M., Clerici, M., Dell'Osso, B. M., Sensi, S. L., Mansur, R. B., Rosenblat, J. D., Martinotti, G., & McIntyre, R. S. (2024). The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data. Journal of Affective Disorders, 348, 314-322. https://doi.org/10.1016/j.jad.2023.12.038

Vancouver

d'Andrea G, Pettorruso M, Di Lorenzo G, Rhee TG, Chiappini S, Carullo R, et al. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data. Journal of Affective Disorders. 2024;348:314-322. doi:10.1016/j.jad.2023.12.038

BibTeX
@article{dAndrea2024,
  author = {d'Andrea, Giacomo and Pettorruso, Mauro and Di Lorenzo, Giorgio and Rhee, Taeho Greg and Chiappini, Stefania and Carullo, Rosalba and Barlati, Stefano and Zanardi, Raffaella and Rosso, Gianluca and Di Nicola, Marco and Andriola, Ileana and Marcatili, Matteo and Clerici, Massimo and Dell'Osso, Bernardo Maria and Sensi, Stefano L and Mansur, Rodrigo B and Rosenblat, Joshua D and Martinotti, Giovanni and McIntyre, Roger S},
  title = {The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data},
  journal = {Journal of Affective Disorders},
  year = {2024},
  volume = {348},
  pages = {314--322},
  doi = {10.1016/j.jad.2023.12.038}
}
Kostenlos starten →